NYSE: ENOV · Medical Devices
Enovis (ENOV) fair value: undervalued or overvalued?
As of 14 Nov 2026, Faircurve's model values Enovis (ENOV) at $32.77 a share. The stock last closed at $27.22, which puts the model's fair value 20.4% above the price. On the model's bands that reads as Undervalued.
Revalued . Price is the close of 17 Nov 2026. Enovis Corporation.
The report adds the live price, the price chart, the next earnings date and the analysts' consensus. No account needed.
This week, in three parts
What happenedThe run of 14 Nov 2026 moved the fair value from $34.98 to $32.77 (-6.3%). The model changed its method this week; the move is not broken down.
What the model makes of itThe price of $27.22 is 20.4% below it: Undervalued, on a medium evidence grade.
What's nextNext report on 25 Feb 2027. The next weekly run is on Saturday 21 Nov 2026.
What price range does the model give ENOV?
The calibrated range for ENOV over 63 trading days is $26.21 to $38.93. There is no live options data for this stock, so the range is built from the fair value and calibrated weekly against realised prices (n = 13,250 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $21.06 to $47.05. In 62% of the simulations the fair value came out above the price the model ran on.
Faircurve Insights · 14 Nov 2026
Enovis Corporation is a global medical technology enterprise. It designs, produces and supplies medical devices.
Faircurve's model put the fair value at $32.77 a share on 14 Nov 2026, the midpoint of 2,000 simulations. The previous run, on 7 Nov 2026, gave $34.98, so the fair value moved -6.3%. The model changed its method this week, and the move is not broken down. The calibrated range over 63 trading days is $26.21 to $38.93, built from the fair value. There is no live options data for the stock. Ranges built this way held the price 60% of the time at this horizon. The model grades the evidence Medium, based on how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say whether the fair value is right.
The model's overall quality score is 52 out of 100, a composite of six factors. Earnings quality scores 100. Stability scores 0, with five-year EBITDA margin downside volatility at 16.7 pts against a peer median of 4.0 pts. The balance sheet scores 70, with net debt to EBITDA at -8.07x against a peer median of 1.73x. The model compares Enovis with Integra LifeSciences Holdings Corporation (IART), UFP Technologies, Inc. (UFPT), Neogen Corporation (NEOG) and Artivion, Inc. (AORT).
Written from the figures on this page for the 14 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
The Global Pulse
Faircurve's note after each US session, in your inbox. No account needed.
When does ENOV report earnings, and how has the stock reacted?
Enovis's next earnings report is scheduled for 25 Feb 2027. Companies can move their dates.
Around its last 8 reports: what the options market priced, and what followed
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across ENOV's last 8 reports, ignoring direction, was 10.7%.
What the options market has priced for a month's move in ENOV
How does ENOV score on business quality?
Enovis's overall quality score is 52 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.
| Factor | Score (0 to 100) | Headline measure | Peer median |
|---|---|---|---|
| ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend. | 33 | 3.2%ROIC | 3.7% |
| Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash). | 100 | ||
| Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes. | 51 | 6.7%Revenue growth, trailing | 5.8% |
| Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks. | 46 | 0.0%Net buybacks / market value | 0.0% |
| Balance sheetNet debt to EBITDA and interest coverage. | 70 | -8.07xNet debt / EBITDA | 1.73x |
| StabilityDownside volatility of the EBITDA margin over the last five years. | 0 | 16.7 ptsEBITDA margin downside volatility, 5y | 4.0 pts |
How does ENOV compare with similar companies?
The companies in medical devices closest to Enovis in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| CNMD CONMED Corporation | $48.39 | $50.43 | +4.2% | Low evidence grade |
| INSP Inspire Medical Systems, Inc. | $59.41 | $61.27 | +3.1% | Low evidence grade |
| TNDM Tandem Diabetes Care, Inc. | $17.06 | $21.89 | +28.3% | Low evidence grade |
| IART Integra LifeSciences Holdings Corporation | $13.55 | $16.00 | +18.1% | Undervalued |
| UFPT UFP Technologies, Inc. | $297.49 | $266.65 | -10.4% | Fairly valued |
| AHCO AdaptHealth Corp. | $7.53 | $7.47 | -0.8% | Low evidence grade |
| NEOG Neogen Corporation | $10.90 | $10.11 | -7.2% | Fairly valued |
| AORT Artivion, Inc. | $18.27 | $20.28 | +11.0% | Fairly valued |
What the comparable companies' multiples alone would give for ENOV, the peer-implied price, is $60.77 a share on this run. The fair value weighs that against the company's own multiple.
Enovis at a glance
Enovis Corporation is a global medical technology enterprise specializing in the design, production, and supply of medical devices.
- Market value
- $1.6B
- Sector
- Healthcare
- Industry
- Medical Devices
- Revenue expected, next twelve months
- $2.4B
- Consensus revenue growth, next fiscal year
- +3.9%
- Analysts with estimates
- 6
- Beta to the US market
- 0.70
- First valued by Faircurve
- 11 Jul 2026
At the close of 17 Nov 2026, 62.4% of the 1,083 graded US stocks the model covers traded below the model's fair value. ENOV was among them.
How the fair value is worked out: the model prices Enovis on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 7 Nov 2026 the model's fair value for ENOV was $34.98. As of 14 Nov 2026 it is $32.77, a change of -6.3%. The model changed its method this week; the move is not broken down. The model revalues every stock it covers each week, and again after an earnings report.
Questions about Enovis's valuation
Is Enovis stock undervalued or overvalued?
On Faircurve's model, ENOV reads as Undervalued as of 14 Nov 2026. The model's fair value is $32.77 a share against a last close of $27.22, a gap of +20.4%.
What is ENOV's fair value?
$32.77 a share as of 14 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $21.06 to $47.05.
What price range does the model give ENOV?
$26.21 to $38.93 over 63 trading days. Ranges built this way held the price 60% of the time across 13,250 past valuations, refreshed 14 Nov 2026.
When does Enovis report earnings next?
The next report is scheduled for 25 Feb 2027. Companies can move their dates.
How much has ENOV moved on past earnings reports?
Across its last 8 reports the median two session move was 10.7%, ignoring direction. The largest was +14.1% around the report of 26 Feb 2026.
How confident is the model in this valuation?
The model's evidence grade for ENOV is medium. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.
The model's own ideas on ENOV
The model holds no idea open on ENOV today. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on ENOV with their outcomes. A free account is enough.